Analysts expect REGENXBIO Inc. to report revenue of 10.22 M for Q3 26, against a range of 9.59 M to 10.84 M. The most recent reported quarter, Q2 26, came in at 108.02 M, a 18.8% beat against the 90.90 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 24.20 M | 21.21 M | 89.01 M | 21.36 M | 29.73 M | 30.34 M | 6.39 M | 108.02 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 24.08 M | 26.21 M | 120.59 M | 45.07 M | 26.02 M | 44.08 M | 29.52 M | 98.87 M | 10.84 M | 26.38 M | 11.06 M | 17.60 M | 13.27 M | 30.14 M | 62.05 M | 157.19 M | ||||||||||
| Low Estimate | 21.62 M | 22.19 M | 109.27 M | 37.57 M | 22.17 M | 40.77 M | 24.39 M | 82.93 M | 9.59 M | 22.43 M | 9.96 M | 15.10 M | 11.03 M | 27.48 M | 54.90 M | 132.83 M | ||||||||||
| Consensus Estimate | 22.85 M | 24.20 M | 114.93 M | 41.32 M | 24.09 M | 42.43 M | 26.96 M | 90.90 M | 10.22 M | 24.40 M | 10.51 M | 16.35 M | 12.15 M | 28.81 M | 58.47 M | 145.01 M |
Analysts expect REGENXBIO Inc. to report earnings per share of -1.36 for Q3 26, against a range of -1.48 to -1.24. The most recent reported quarter, Q2 26, came in at 0.43, a 514.3% beat against the 0.07 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.17 | -1.01 | 0.12 | -1.38 | -1.20 | -1.30 | -1.72 | 0.43 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -1.01 | -1.02 | 0.53 | -0.90 | -1.25 | -0.88 | -1.30 | 0.08 | -1.24 | -0.99 | -1.13 | -0.97 | -1.39 | -1.01 | -0.40 | -0.15 | ||||||||||
| Low Estimate | -1.17 | -1.12 | 0.45 | -1.04 | -1.37 | -0.94 | -1.44 | 0.06 | -1.48 | -1.09 | -1.25 | -1.09 | -1.67 | -1.17 | -0.46 | -0.17 | ||||||||||
| Consensus Estimate | -1.09 | -1.07 | 0.49 | -0.97 | -1.31 | -0.91 | -1.37 | 0.07 | -1.36 | -1.04 | -1.19 | -1.03 | -1.53 | -1.09 | -0.43 | -0.16 |
Pull Wall Street consensus for REGENXBIO Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=RGNX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "RGNX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=RGNX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();